Drug discovery possibilities from visfatin cardioprotection?

Current Opinion in Pharmacology

Volumn 9, Issue 2, 2009, Pages 202-207

  Hausenloy, Derek J ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ATORVASTATIN; BRADYKININ; FIBRINOLYTIC AGENT; INHALATION ANESTHETIC AGENT; NATRIURETIC FACTOR; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OPIATE DERIVATIVE;

ACUTE CORONARY SYNDROME; ANGIOGENESIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG RESPONSE; DRUG SYNTHESIS; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; INSULIN SENSITIVITY; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; REPERFUSION INJURY; REVIEW; SINGLE DRUG DOSE;

ANIMALS; ATHEROSCLEROSIS; CARDIOTONIC AGENTS; DRUG DISCOVERY; ENDOTHELIAL CELLS; HUMANS; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PHYSIOLOGIC; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; REPERFUSION INJURY;

EID: 62249179991     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2008.10.005     Document Type: Review

References (45)

1. Stephens J.M., and Vidal-Puig A.J. An update on visfatin/pre-B cell colony-enhancing factor, an ubiquitously expressed, illusive cytokine that is regulated in obesity. Curr Opin Lipidol 17 (2006) 128-131
2. Adeghate E. Visfatin: structure, function and relation to diabetes mellitus and other dysfunctions. Curr Med Chem 15 (2008) 1851-1862
3. Fukuhara A., Matsuda M., Nishizawa M., Segawa K., Tanaka M., Kishimoto K., Matsuki Y., Murakami M., Ichisaka T., Murakami H., et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307 (2005) 426-430. This study was the first to identify visfatin as a novel adipocytokine capable of mimicking the glucose-lowering effect of insulin. However, the data suggesting that it acted at the level of the insulin receptor were questioned resulting in a later retraction of this study (see reference [5]).
4. Hausenloy D.J., and Yellon D.M. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev 12 (2007) 217-234
5. Fukuhara A., Matsuda M., Nishizawa M., Segawa K., Tanaka M., Kishimoto K., Matsuki Y., Murakami M., Ichisaka T., Murakami H., et al. Retraction. Science 318 (2007) 565
6. Song H.K., Lee M.H., Kim B.K., Park Y.G., Ko G.J., Kang Y.S., Han J.Y., Han S.Y., Han K.H., Kim H.K., et al. Visfatin: a new player in mesangial cell physiology and diabetic nephropathy. Am J Physiol Renal Physiol 295 (2008) F1485-F1494
7. Haider D.G., Holzer G., Schaller G., Weghuber D., Widhalm K., Wagner O., Kapiotis S., and Wolzt M. The adipokine visfatin is markedly elevated in obese children. J Pediatr Gastroenterol Nutr 43 (2006) 548-549
8. Tan B.K., Chen J., Digby J.E., Keay S.D., Kennedy C.R., and Randeva H.S. Increased visfatin messenger ribonucleic Acid and protein levels in adipose tissue and adipocytes in women with polycystic ovary syndrome: parallel increase in plasma visfatin. J Clin Endocrinol Metab 91 (2006) 5022-5028
9. Krzyzanowska K., Krugluger W., Mittermayer F., Rahman R., Haider D., Shnawa N., and Schernthaner G. Increased visfatin concentrations in women with gestational diabetes mellitus. Clin Sci (Lond) 110 (2006) 605-609
10. Haider D.G., Pleiner J., Francesconi M., Wiesinger G.F., Muller M., and Wolzt M. Exercise training lowers plasma visfatin concentrations in patients with type 1 diabetes. J Clin Endocrinol Metab 91 (2006) 4702-4704
11. Retnakaran R., Youn B.S., Liu Y., Hanley A.J., Lee N.S., Park J.W., Song E.S., Vu V., Kim W., Tungtrongchitr R., et al. Correlation of circulating full-length visfatin (PBEF/Nampt) with metabolic parameters in subjects with and without diabetes: a crosssectional study. Clin Endocrinol 69 (2008) 885-893
12. Haider D.G., Schindler K., Schaller G., Prager G., Wolzt M., and Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 91 (2006) 1578-1581
13. Chan T.F., Chen Y.L., Lee C.H., Chou F.H., Wu L.C., Jong S.B., and Tsai E.M. Decreased plasma visfatin concentrations in women with gestational diabetes mellitus. J Soc Gynecol Invest 13 (2006) 364-367
14. Pagano C., Pilon C., Olivieri M., Mason P., Fabris R., Serra R., Milan G., Rossato M., Federspil G., and Vettor R. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 91 (2006) 3165-3170
15. Krzyzanowska K., Mittermayer F., Krugluger W., Kopp H.P., and Schernthaner G. Increase in visfatin after weight loss induced by gastroplastic surgery. Obesity (Silver Spring) 14 (2006) 1886-1889
16. Samal B., Sun Y., Stearns G., Xie C., Suggs S., and McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 14 (1994) 1431-1437
17. Ye S.Q., Zhang L.Q., Adyshev D., Usatyuk P.V., Garcia A.N., Lavoie T.L., Verin A.D., Natarajan V., and Garcia J.G. Pre-B-cell-colony-enhancing factor is critically involved in thrombin-induced lung endothelial cell barrier dysregulation. Microvasc Res 70 (2005) 142-151
18. Ognjanovic S., Bao S., Yamamoto S.Y., Garibay-Tupas J., Samal B., and Bryant-Greenwood G.D. Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes. J Mol Endocrinol 26 (2001) 107-117
19. Jia S.H., Li Y., Parodo J., Kapus A., Fan L., Rotstein O.D., and Marshall J.C. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 113 (2004) 1318-1327. This experimental study was the first to suggest that visfatin/PBEF had the ability to attenuate the neutrophil apoptosis induced by inflammation and sepsis, implying that visfatin/PBEF may contribute to cellular survival.
20. van d V., Nong Z., O'Neil C., Urquhart B., Freeman D., and Pickering J.G. Pre-B-cell colony-enhancing factor regulates NAD+-dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation. Circ Res 97 (2005) 25-34
21. Rongvaux A., Shea R.J., Mulks M.H., Gigot D., Urbain J., Leo O., and Andris F. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol 32 (2002) 3225-3234
22. Hasmann M., and Schemainda I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res 63 (2003) 7436-7442
23. Khan J.A., Tao X., and Tong L. Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents. Nat Struct Mol Biol 13 (2006) 582-588
24. Yang H., Lavu S., and Sinclair D.A. Nampt/PBEF/Visfatin: a regulator of mammalian health and longevity?. Exp Gerontol 41 (2006) 718-726
25. Shibata R., Sato K., Pimentel D.R., Takemura Y., Kihara S., Ohashi K., Funahashi T., Ouchi N., and Walsh K. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 11 (2005) 1096-1103. This important experimental study was among the first to link an adipocytokine, in this case, adiponectin, with cardioprotection. Crucially, this protective effect was dependent on a receptor-mediated activation of intracellular signalling pathways indicating that a direct cardioprotective effect at the level of the cardiomyocyte.
26. Simpkin J.C., Yellon D.M., Davidson S.M., Lim S.Y., Wynne A.M., and Smith C.C. Apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemiareperfusion injury. Basic Res Cardiol 102 (2007) 518-528
27. Smith C.C., Mocanu M.M., Davidson S.M., Wynne A.M., Simpkin J.C., and Yellon D.M. Leptin, the obesity-associated hormone, exhibits direct cardioprotective effects. Br J Pharmacol 149 (2006) 5-13
28. Sivaraman V., Mudalgiri N.R., Di Salvo C., Kolvekar S., Hayward M., Yap J., Keogh B., Hausenloy D.J., and Yellon D.M. Postconditioning protects human atrial muscle through the activation of the RISK pathway. Basic Res Cardiol 102 (2007) 453-459
29. Hausenloy D.J., Wynne A.M., and Yellon D.M. Ischemic preconditioning targets the reperfusion phase. Basic Res Cardiol 102 (2007) 445-452
30. Davidson S.M., Hausenloy D., Duchen M.R., and Yellon D.M. Signalling via the reperfusion injury signalling kinase (RISK) pathway links closure of the mitochondrial permeability transition pore to cardioprotection. Int J Biochem Cell Biol 38 (2006) 414-419
31. Hausenloy D.J., and Yellon D.M. Preconditioning and postconditioning: united at reperfusion. Pharmacol Ther 116 (2007) 173-191
32. Hausenloy D.J., and Yellon D.M. The mitochondrial permeability transition pore: its fundamental role in mediating cell death during ischaemia and reperfusion. J Mol Cell Cardiol 35 (2003) 339-341
33. Jonassen A.K., Sack M.N., Mjos O.D., and Yellon D.M. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res 89 (2001) 1191-1198
34. Segawa K., Fukuhara A., Hosogai N., Morita K., Okuno Y., Tanaka M., Nakagawa Y., Kihara S., Funahashi T., Komuro R., et al. Visfatin in adipocytes is upregulated by hypoxia through HIF1alpha-dependent mechanism. Biochem Biophys Res Commun 349 (2006) 875-882
35. Bae S.K., Kim S.R., Kim J.G., Kim J.Y., Koo T.H., Jang H.O., Yun I., Yoo M.A., and Bae M.K. Hypoxic induction of human visfatin gene is directly mediated by hypoxia-inducible factor-1. FEBS Lett 580 (2006) 4105-4113
36. Eckle T., Kohler D., Lehmann R., El Kasmi K., and Eltzschig H.K. Hypoxia-inducible factor-1 is central to cardioprotection: a new paradigm for ischemic preconditioning. Circulation 118 (2008) 166-175
37. Adya R., Tan B.K., Punn A., Chen J., and Randeva H.S. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res 78 (2008) 356-365
38. Rongvaux A., Galli M., Denanglaire S., Van Gool F., Dreze P.L., Szpirer C., Bureau F., Andris F., and Leo O. Nicotinamide phosphoribosyl transferase/pre-B cell colony-enhancing factor/visfatin is required for lymphocyte development and cellular resistance to genotoxic stress. J Immunol 181 (2008) 4685-4695
39. Lim S.Y., Davidson S.M., Paramanathan A.J., Smith C.C., Yellon D.M., and Hausenloy D.J. The novel adipocytokine visfatin exerts direct cardioprotective effects. J Cell Mol Med 12 (2008) 1395-1403
40. Yilmaz M.I., Saglam M., Carrero J.J., Qureshi A.R., Caglar K., Eyileten T., Sonmez A., Cakir E., Yenicesu M., Lindholm B., et al. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol Dial Transplant 23 (2008) 959-965
41. Takebayashi K., Suetsugu M., Wakabayashi S., Aso Y., and Inukai T. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism 56 (2007) 451-458
42. Kim S.R., Bae Y.H., Bae S.K., Choi K.S., Yoon K.H., Koo T.H., Jang H.O., Yun I., Kim K.W., Kwon Y.G., et al. Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells. Biochim Biophys Acta 1783 (2008) 886-895
43. Kim S.R., Bae S.K., Choi K.S., Park S.Y., Jun H.O., Lee J.Y., Jang H.O., Yun I., Yoon K.H., Kim Y.J., et al. Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2. Biochem Biophys Res Commun 357 (2007) 150-156
44. Dahl T.B., Yndestad A., Skjelland M., Oie E., Dahl A., Michelsen A., Damas J.K., Tunheim S.H., Ueland T., Smith C., et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 115 (2007) 972-980
45. Adya R., Tan B.K., Chen J., and Randeva H.S. Nuclear factor-kappaB induction by visfatin in human vascular endothelial cells: its role in MMP-2/9 production and activation. Diabetes Care 31 (2008) 758-760